Literature DB >> 12040919

TLR4 and LPS hyporesponsiveness in humans.

David A Schwartz1.   

Abstract

Asthma is a complex genetic disorder that is caused by a number of unique gene-gene and gene-environment interactions. The search for asthma susceptibility genes has been complicated by the broad clinical phenotype of asthma, the polygenic inheritance pattern of this disease, and the substantial role of environmental exposures in the development and progression of asthma. Inhaled environmental agents induce several biologic responses in asthmatics; including the induction of acquired and innate immunity that leads to acute and chronic forms of airway inflammation and airway remodeling. Acquired immune responses to protein antigens, such as house dust mite allergen, often induce type 2 T lymphocyte-driven responses (Th2) which appear to be important in atopic asthma. Recent studies by our group and others demonstrate that innate immunity, initiated by inhalation of bacterial and viral pathogens, organic dusts, endotoxin or lipopolysaccharide (LPS), air pollution particulate matter, and ozone, can also cause acute and chronic forms of airflow obstruction, airway inflammation, and even airway remodeling. Emerging evidence indicates that both acquired and innate immune responses in the lung may be influenced by polymorphic genes. For instance, functional polymorphisms in the IL-4 receptor gene are thought to preferentially stimulate acquired Th2 immune responses to inhaled allergens, and we have recently shown that common co-segregating mutations in TLR4 (a transmembrane receptor for LPS) are associated with diminished airway responsiveness to inhaled LPS. These observations suggest that environmental challenges can be used to narrow the phenotype of asthma and allow scientists to investigate unique gene-environment interactions that are involved in the development of biologically specific forms of asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040919     DOI: 10.1078/1438-4639-00117

Source DB:  PubMed          Journal:  Int J Hyg Environ Health        ISSN: 1438-4639            Impact factor:   5.840


  9 in total

1.  Innate immunity SNPs are associated with risk for severe sepsis after burn injury.

Authors:  Robert C Barber; Ling-Yu E Chang; Brett D Arnoldo; Gary F Purdue; John L Hunt; Jureta W Horton; Corinne C Aragaki
Journal:  Clin Med Res       Date:  2006-12

2.  In vivo lung perfusion rehabilitates sepsis-induced lung injury.

Authors:  J Hunter Mehaffey; Eric J Charles; Sarah Schubert; Morgan Salmon; Ashish K Sharma; Dustin Money; Mark H Stoler; Victor E Laubach; Curtis G Tribble; Mark E Roeser; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2017-09-14       Impact factor: 5.209

3.  TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury.

Authors:  R C Barber; C C Aragaki; F A Rivera-Chavez; G F Purdue; J L Hunt; J W Horton
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

4.  Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis.

Authors:  A Gagro; M Tominac; V Krsulović-Hresić; A Baće; M Matić; V Drazenović; G Mlinarić-Galinović; E Kosor; K Gotovac; I Bolanca; S Batinica; S Rabatić
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

5.  TLR4 preconditioning is associated with low success of OK-432 treatment for lymphatic malformations in children.

Authors:  Marc Reismann; Nader Ghaffarpour; Ethel Luvall; Adan Jirmo; Josephine Radtke; Gösta Claesson; Tomas Wester
Journal:  Pediatr Surg Int       Date:  2016-01-22       Impact factor: 1.827

Review 6.  New insight into immunity and immunopathology of Rickettsial diseases.

Authors:  Pasquale Mansueto; Giustina Vitale; Antonio Cascio; Aurelio Seidita; Ilenia Pepe; Antonio Carroccio; Salvatore di Rosa; Giovam Battista Rini; Enrico Cillari; David H Walker
Journal:  Clin Dev Immunol       Date:  2011-09-06

7.  Genetic polymorphism in CD14 gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease.

Authors:  Shweta Kapil; Ajay Duseja; Bal Krishan Sharma; Bhupesh Singla; Anuradha Chakraborti; Ashim Das; Pallab Ray; Radha K Dhiman; Yogesh Chawla
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

8.  First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.

Authors:  Macarena Hernández-Jiménez; Samuel Martín-Vílchez; Dolores Ochoa; Gina Mejía-Abril; Manuel Román; Paola Camargo-Mamani; Sergio Luquero-Bueno; Bernd Jilma; María A Moro; Gerónimo Fernández; David Piñeiro; Marc Ribó; Víctor M González; Ignacio Lizasoain; Francisco Abad-Santos
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-09       Impact factor: 8.886

9.  Association of the TLR4 Asp299Gly polymorphism with lung function in relation to body mass index.

Authors:  Punam Pahwa; Chandima P Karunanayake; Donna C Rennie; Yue Chen; David A Schwartz; James A Dosman
Journal:  BMC Pulm Med       Date:  2009-09-21       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.